The speculation comes as Dentsply ( NASDAQ: XRAY) said Tuesday it started a process to evaluate strategic alternatives for ...

Fintel reports that on February 14, 2025, Wells Fargo initiated coverage of DENTSPLY SIRONA (NasdaqGS:XRAY) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 21.64% Upside As of ...

CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company has initiated a process to evaluate ...

DENTSPLY SIRONA (XRAY) has initiated a process to evaluate strategic alternatives for its Wellspect Healthcare business. Wellspect is a leading ...

The projected annual revenue for DENTSPLY SIRONA is 4,298MM, an increase of 10.21%. The projected annual non-GAAP EPS is 2.29. First Eagle Investment Management holds 14,500K shares representing 7 ...

the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position. Revenue Growth: Dentsply Sirona's ...

Dentsply Sirona initiated a process to evaluate strategic alternatives for its Wellspect Healthcare business. Wellspect, a provider of bladder and bowel management care products, has an estimated $2 ...

CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona ... which has an estimated $2 billion total addressable market. “We have initiated a review of ...

Key Indicators: Dentsply Sirona's Financial Health Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers.

M Company, Ivoclar Vivadent AG, Dentsply Sirona Inc., Nobel Biocare Services AG, and BioHorizons IPH Inc. Lead the ...